

Pharmacologic Intervention in the Evaluation of Biliary Disorders with Emphasis on Chronic Acalculous Biliary Diseases

Chun Ki Kim, M.D.

*Associate Director, Nuclear Medicine, Department of Radiology
Mount Sinai School of Medicine, Mount Sinai Medical Center
New York, NY, USA*

Over the past decade, pharmacologic interventions have been increasingly used in conjunction with hepatobiliary scintigraphy to enhance the diagnostic information for the evaluation of acute and chronic calculous and acalculous biliary tract diseases.

Sincalide (Kinevac, Squibb Diagnostics, Princeton, NJ), a synthetic C-terminal octapeptide of CCK, has been used to evaluate gallbladder ejection fraction and/or sphincter of Oddi response in patients with suspected chronic, acalculous biliary tract diseases to determine who could benefit from cholecystectomy or sphincterotomy. Administration technique for sincalide is of utmost importance. Although the optimal dose and duration of infusion is the subject of some controversy^{1,2)}, a long infusion seems to produce more complete gallbladder emptying and less severe side effects than a short infusion, probably due to the 2.5-minute plasma half-life of sincalide.

Controversies also exist over the use of CCK for the evaluation of chronic acalculous biliary disorders. The overall data, however, favor the use of this test for the diagnosis of chronic acalculous gallbladder and cystic duct disease as well as sphincter of Oddi dysfunction. A detailed discussion on this subject can be found in a recent review³⁾.

Recent data and reanalysis of the literature suggest that morphine augmented cholescintigraphy has a reasonably good, though imperfect, specificity and positive predictive value, which are significantly better than for delayed imaging, in addition to its logistical advantage (shortening the imaging time)⁴⁻⁶⁾. Sincalide has also been used in the diagnosis of acute cholecystitis in order to empty the gallbladder before cholescintigraphy so gallbladder filling can be enhanced during the study if the cystic duct is patent^{7,8)}. Sincalide pretreatment, when administered at the physiologic rate, will be helpful in conditions in which functional resistance to tracer flow into the gallbladder may be present. However, morphine-augmentation will further improve the efficacy of the test even after sincalide pretreatment⁹⁻¹¹⁾.

There are certain conditions and medications that may affect gallbladder contraction¹²⁻¹⁶⁾. Several variants associated with CCK preadministration and morphine have also been reported, which are often unrecognized by nuclear medicine physicians. These include:

- 1) delayed tracer excretion into the bowel associated with prompt and progressive

- gallbladder filling after sincalide pretreatment¹⁷⁾,
- 2) morphine administration increases the frequency and the degree of duodenogastric reflux^{18, 19)}.
 - 3) variable degree and duration of bile retention on cholescintigraphy after morphine administration for evaluation of acute cholecystitis²⁰⁾. The impact of this variable or no visible effect of morphine on the efficacy of morphine-augmented cholescintigraphy is yet unclear, and further study will be necessary.

In summary, cholescintigraphy has played a pivotal role in the evaluation of various biliary tract diseases, particularly with increasing uses of pharmacologic intervention. The physician monitoring the study should employ the most optimal technique for the pharmacologic intervention, i.e., the dose and the rate of administration. Certain conditions and medications that may affect gallbladder contraction should be remembered. It is also important to be aware of the various physiologic and pharmacologic effects on imaging findings: not only those findings that are normal but also the undesirable variants. Failure to recognize such effects can lead to incorrect interpretations.

REFERENCES

- 1) Krishnamurthy S, Krishnamurthy GT: *Quantitative assessment of hepatobiliary disease with Tc-99m-IDA scintigraphy*. In: Freeman LM, Weissman HS, eds. *Nuclear Medicine Annual, New York : Raven Press, 1988;309-330*
- 2) Ziessman HA, Fahey FH, Hixson DJ: *Calculation of a gallbladder ejection fraction: advantage of continuous sincalide infusion over the three-minute infusion method*. *J Nucl Med 1992;33:537-541*
- 3) Kim CK, Worsley DF, Machac J: *Interventions in gastrointerventional nuclear medicine*. In Freeman LM (ed), *Nuclear Medicine Annual 1996, Raven Press, New York, 1996; 213-257*
- 4) Kim CK, Juweid M, Woda A, et al: *Hepatobiliary scintigraphy: morphine-augmented versus delayed imaging in patients with suspected acute cholecystitis*. *J Nucl Med 1993;34:506-509*
- 5) Kim CK, Tse KM, Juweid M, et al: *Cholescintigraphy in the diagnosis of acute cholecystitis: morphine-augmentation is superior to delayed imaging*. *J Nucl Med 1993; 34:1866-1870*
- 6) Cabana MD, Alavi A, Berlin JA, et al: *Morphine-augmented hepatobiliary scintigraphy: A meta-analysis*. *Nucl Med Commun 1995;16:1068-1071*
- 7) Eikman EA, Cameron JL, Colman M, Natarajan TK, Dugal P, Wagner HN: *A test for patency of the cystic duct in acute cholecystitis*. *Ann Intern Med 1975; 82:318-322*
- 8) Fink-Bennett D: *Augmented cholescintigraphy: its roles in detecting acute and chronic disorders of the hepatobiliary tree*. *Semin Nucl Med. 1991;21:128-139*
- 9) Kim CK, Goyal M, San Pedro E, Ozgen P, Alavi A: *The effect of CCK pretreatment on*

- gallbladder visualization on delayed or morphine-augmented imaging. (abstract) J Nucl Med 1995;36:74P*
- 10) Chen CC, Holder LE, Maunoury C, Drachenberg CI: *Morphine: augmentation increases gallbladder visualization in patients pretreated with cholecystokinin. J Nucl Med 1997 April issue (in press)*
 - 11) Kim CK: *Editorial: Pharmacologic intervention for the diagnosis of acute cholecystitis: cholecystokinin pretreatment or morphine, or both?. J Nucl Med 1997 April issue (In press)*
 - 12) Garrigues V, Ponce J, Cano C, et al.: *Effect of selective and nonselective muscarinic blockade on cholecystokinin-induced gallbladder emptying in man. Dig Dis Sci 1992;37: 101-104*
 - 13) Zhu XF, Harris AG, Yang MF, et al.: *Effect of octreotide on dynamic excretion of bile in Chinese acromegalic patients assessed by [^{99m}Tc]EHIDA hepatobiliary scan. Dig Dis Sci 1994; 39:284-288*
 - 14) Grimaldi C, Darcourt J, Harris AG, et al.: *Cholescintigraphic study of effect of somatostatin analog, octreotide, on bile secretion and gallbladder emptying in normal subjects. Dig Dis Sci 1993;38:1718-21*
 - 15) Annese V, Caruso N, Accadia L, et al.: *Gallbladder function and gastric liquid emptying in achalasia. Dig Dis Sci 1991;36:1116-1120*
 - 16) Pechlivanides G, Xynos E, Chrysos E, et al.: *Gallbladder emptying after antiulcer gastric surgery. Am J Surg 1994;168:335-339*
 - 17) Kim CK, Palestro CJ, Solomon RW, et al.: *Delayed biliary-to-bowel transit in cholecintigraphy after cholecystokinin treatment. Radiology 1990;176:553-556*
 - 18) Oates E, Achong DM: *Incidence and significance of enterogastric reflux during morphine- augmented cholescintigraphy. Clin Nucl Med 1992;17:926-8*
 - 19) Shih WJ, Lee JK, Magoun S, et al.: *Morphine-augmented cholescintigraphy enhances duodenogastric reflux. Ann Nucl Med. 1995;9:225-8*
 - 20) Kim CK, Lim JK, Machac J: *Variable bile retention on cholescintigraphy after morphine administration. Eur J Nucl Med 1996;23:1464-1467*